Shots:

• The BLA is based on two P-III study results assessing efficacy- safety and PK of IBI-305 vs bevacizumab in patients with advanced non-sq NSCLC and has demonstrated in meeting 1EPs with bio-similarity
• Innovent has received three NMPA acceptance including IBI-305 namely Tyvyt (sintilimab injection) and IBI-303 (adalimumab- biosimilar) in H2’18 for ankylosing spondylitis (AS)- rheumatoid arthritis (RA) & psoriasis and r/r classical Hodgkin's lymphoma respectively
• Avastin’s biosimilar IBI-305 (bevacizumab) is an anti-VEGF mAb- involved in inhibiting PI3K-Akt/PKB & Ras-Raf-MEK-ERK pathways and targeted for NSCLC- colorectal cancer and other malignant tumors

  Ref: PRNewswire | Image: Innovent